{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16 in Participants Who Received Risankizumab Compared With Placebo (Part A)', 'OutcomeMeasureDescription': 'The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema (E), induration (I), and desquamation (D) are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all three; Almost clear (1) = mean >0, <1.5; Mild (2) = mean ≥1.5, <2.5; Moderate (3) = mean ≥2.5, <3.5; and Severe (4) = mean ≥3.5. NRI was used for missing data.', 'OutcomeMeasurePopulationDescription': 'ITT population', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': 'Week 16', 'OutcomeGroupList': {'OutcomeGroup': [
            {'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Placebo (Part A)', 'OutcomeGroupDescription': 'Participants randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).'
            },
            {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Risankizumab (Part A)', 'OutcomeGroupDescription': 'Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).'
            }
        ]
    }, 'OutcomeDenomList': {'OutcomeDenom': [
            {'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [
                        {'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '102'
                        },
                        {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '304'
                        }
                    ]
                }
            }
        ]
    }, 'OutcomeClassList': {'OutcomeClass': [
            {'OutcomeCategoryList': {'OutcomeCategory': [
                        {'OutcomeMeasurementList': {'OutcomeMeasurement': [
                                    {'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '7.8'
                                    },
                                    {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '87.8'
                                    }
                                ]
                            }
                        }
                    ]
                }
            }
        ]
    }, 'OutcomeAnalysisList': {'OutcomeAnalysis': [
            {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001'
                    ]
                }, 'OutcomeAnalysisNonInferiorityType': 'Other', 'OutcomeAnalysisPValue': '<0.001', 'OutcomeAnalysisPValueComment': 'Cochran-Mantel-Haenszel test adjusted for strata (baseline weight [≤100 kg vs >100 kg
                ] and prior exposure to TNF antagonists [
                    0 vs ≥1
                ]). If there was a stratum containing zero count,
                0.1 was added to each cell.', 'OutcomeAnalysisStatisticalMethod': 'Cochran-Mantel-Haenszel', 'OutcomeAnalysisParamType': 'adjusted difference in percentage', 'OutcomeAnalysisParamValue': '79.9', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '73.5', 'OutcomeAnalysisCIUpperLimit': '86.3', 'OutcomeAnalysisEstimateComment': '95% CI for adjusted difference of 2 treatment groups, calculated by Cochran-Mantel-Haenszel test adjusted for strata. If there was a stratum containing zero count,
                0.1 was added to each cell.'
            }
        ]
    }
}